SUBSCRIBE
SUBSCRIBE

Gilead Sciences, Inc.

NEWS
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Job Trends
Gilead to Unveil New SoCal Facility That Could House Up to 500 Employees
August 16, 2017
 · 
2 min read
Deals
Why Gilead Might Do ‘Nothing In Oncology’ As Key Drugs Topple
August 11, 2017
 · 
1 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Policy
Gilead’s HIV Triple Combo Gets Sped-up FDA Review, Decision Date Locked Down
August 11, 2017
 · 
3 min read
Biotech Bay
Is AbbVie About to Deliver a Blow to Gilead’ Guidance?
August 7, 2017
 · 
1 min read
Business
5 Things Gilead’s Q2 Earnings Numbers Didn’t Tell You
August 1, 2017
 · 
1 min read
Biotech Bay
Why Gilead Should Consider Breaking The Company Up Into Two
July 27, 2017
 · 
1 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
FDA
FDA Green Lights Gilead’s Vosevi, With a Black Box Warning Attached
July 19, 2017
 · 
2 min read
Deals
Why Incyte Is Still A Good Backup Plan For Gilead
July 14, 2017
 · 
1 min read
Deals
Gilead’s History Of Acquisitions Could Predict The Type Of Deal The Biotech Is Looking For
July 10, 2017
 · 
1 min read
Load More
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Biotech Bay
Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21
February 8, 2018
 · 
1 min read
Business
Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results
February 6, 2018
 · 
29 min read
Business
Jacqueline K. Barton, Ph.D., Joins Gilead Sciences’ Board of Directors
February 1, 2018
 · 
2 min read
Business
Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018
January 23, 2018
 · 
1 min read
Business
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
January 18, 2018
 · 
11 min read
Business
Cypralis and Gilead Agree on License Terms Under Which Cypralis Will Hold Exclusive Development and Commercialization Rights to Certain Jointly-Owned ‘Cyprolides’ for Acute and Chronic Degenerative Diseases
January 8, 2018
 · 
1 min read
Dana-Farber Cancer Institute Joins the Parker Inst
Business
In the Nick of Time: Galapagos Nabs Co-Promotion Filgotinib Deal With Gilead
December 15, 2017
 · 
6 min read
Business
Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
December 14, 2017
 · 
1 min read
FDA Advisory Committee Scheduled to Review Lipocin
Drug Development
71% of ALL Patients Achieved Complete Tumor Remission on Gilead, Kite’s CAR-T Therapy
December 11, 2017
 · 
5 min read
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
December 10, 2017
 · 
13 min read
Load More